Fujifilm Corporation’s Life Sciences Group has rebranded its key companies to better align their strategic focus and reinforce their position as partners throughout the drug development lifecycle. The changes highlight Fujifilm’s commitment to providing integrated solutions from discovery through to commercial manufacturing.

FUJIFILM Irvine Scientific is now FUJIFILM Biosciences, reflecting its evolution from a cell culture media pioneer to a broad provider of life sciences products. This includes discovery reagents, recombinant growth factors, specialty chemicals, and assay materials alongside cell culture media in the US. The legal entity name change will take effect January 1, 2026. Meanwhile, FUJIFILM Diosynth Biotechnologies becomes FUJIFILM Biotechnologies, continuing to offer global contract development and manufacturing organization (CDMO) services for biologics, advanced therapies, and vaccines, with operations in Europe and the US.

Toshihisa Iida, director and general manager of life sciences strategy at Fujifilm Corporation, said the unified “Partners for Life” brand offers complete solutions for pharmaceutical and biotechnology customers. He added: “Unifying under a single banner will simplify engagement for our global network of customers across the entire product development and biomanufacturing spectrum. By combining our proprietary technologies, such as AI and sensing cultivated in imaging and healthcare, we create new value and support pharmaceutical companies, biotech firms, and academia in both drug discovery support solutions and CDMO services.”

Brandon Pence, president of FUJIFILM Biosciences, highlighted the company’s commitment to customer service and innovation: “FUJIFILM Biosciences focuses on supporting our partners in their life sciences ambitions and doing what we can to enable their success along the way. Our foundation is based upon the core principles of putting our people first, transforming through innovation and science, and maintaining a commitment to unprecedented customer service.”

Lars Petersen, CEO of FUJIFILM Biotechnologies, emphasized how the rebranding strengthens collaboration: “This closer coordination and united focus strengthens how we interact and deliver for our customers. Together, we offer deep knowledge and experience, speed, flexibility, and scientific rigor—critical elements in bringing complex biologics to life.”

Over the past 15 years, Fujifilm has invested more than $10 billion through expansions and acquisitions to build its life sciences capabilities.